The hydrodynamically relevant endothelial cell glycocalyx observed in vivo is absent in vitro.
In recent years, the endothelial cell surface glycocalyx has emerged as a structure of fundamental importance to a broad range of phenomena that determine cardiovascular health and disease. This new understanding of the functional significance of the glycocalyx has been made possible through recently developed experimental techniques using intravital microscopy that are capable of directly probing the glycocalyx in vivo. Using fluorescent microparticle image velocimetry in venules and endothelialized cylindrical collagen microchannels, we show that the hydrodynamically relevant endothelial cell glycocalyx surface layer observed in microvessels in vivo (0.52+/-0.28 microm thickness), which is a fundamental determinant of the hydrodynamic and mechanical environment at the endothelial cell surface, is absent from human umbilical vein (0.03+/-0.04 microm thickness) and bovine aortic (0.02+/-0.04 microm thickness) endothelial cells grown and maintained under standard cell culture conditions in vitro. An endothelial surface-bound glycosaminoglycan layer, not necessarily indicative of but having similar hydrodynamic properties to the endothelial glycocalyx observed in vivo, was detected (0.21+/-0.27 microm thickness) only after hyaluronan and chondroitin sulfate were added to the cell culture media at hyperphysiological concentrations (0.2 mg/mL perfused for 75 minutes). The implications of this glycocalyx deficiency under standard cell culture conditions in these pervasive in vitro models broadly impact a myriad of studies involving endothelial cell monolayers in which inferences are made that may depend on endothelial cell surface chemistry. In light of these findings, conclusions drawn from such studies in the areas of microvascular permeability, inflammation, mechanotransduction, and atherosclerosis must be carefully reconsidered.
Potter
Daniel R
DR
Department of Biomedical Engineering, Boston University, 44 Cummington St, Boston, MA 02215, USA.
Damiano
Edward R
ER
D000818:Animals; D001011:Aorta / Q000187:drug effects / Q000473:pathology / Q000502:physiology; D001783:Blood Flow Velocity / Q000502:physiology; D002417:Cattle; D002478:Cells, Cultured; D002809:Chondroitin Sulfates / Q000494:pharmacology; D004730:Endothelium, Vascular / Q000187:drug effects / Q000473:pathology / Q000502:physiology*; D019276:Glycocalyx / Q000502:physiology*; D006801:Humans; D006820:Hyaluronic Acid / Q000494:pharmacology; D016014:Linear Models; D008297:Male; D040542:Mechanotransduction, Cellular / Q000502:physiology*; D051379:Mice; D008810:Mice, Inbred C57BL; D008833:Microcirculation / Q000502:physiology; D018482:Muscle, Skeletal / Q000098:blood supply; D012039:Regional Blood Flow / Q000502:physiology; D012212:Rheology / Q000379:methods; D014471:Umbilical Veins / Q000187:drug effects / Q000473:pathology / Q000502:physiology; D014699:Venules / Q000187:drug effects / Q000473:pathology / Q000502:physiology
D006820:Hyaluronic Acid; D002809:Chondroitin Sulfates